Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
EBMT 2022
We recently interviewed @michaelwangmd of @MDAndersonNews to hear the results of the Phase I/II trial investigating sonrotoclax monotherapy in patients with R/R #MantleCellLymphoma who had previously been treated with a BTKi.
Click here to watch: 👉
Sonrotoclax monotherapy in R/R MCL previously treated with a BTKi: early Phase I/II results
Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents the early results of th...
ow.ly
We are thrilled to once again be the official media partner for the annual EBMT-EHA European CAR T-cell Meeting, which will take place in Palma de Mallorca, Spain, from 12–14 February! 🇪🇸
Want to join us there or attend virtually?
Register here:
👉 https://ow.ly/4WLv50XT1IT..
#ASH25 | @jenweiying of @MDAndersonNews shares results of the Phase II SAVE study evaluating the all-oral combination of revumenib, ASTX727, and venetoclax in newly diagnosed, unfit patients with NPM1-m or KMT2A-r AML.
Click here to watch:
🎥
#AMLsm
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML
Wei-Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, The University of Texas MD Anderson Cancer Center, Houston, TX, ...
ow.ly
🎥 Karthik Ramasamy of @OUHospitals discusses the initial results from a cohort of the RADAR trial, which is evaluating the efficacy of Isa-VRDc induction and Isa-VRD consolidation in newly diagnosed transplant-eligible patients with double hit ultra-high risk #myeloma:
👉
The biggest #ASH25 takeaways, discussed by global experts 💡 🌍
Join our Post ASH 2025 Highlights webinar series 💻 🩸
🗓️ 22nd Jan - 11th Feb
Covering: #AML (@Daver_Leukemia) , Multiple #Myeloma, #CLL, #Lymphoma (@DrJasonWestin), #MPNs (@harrisoncn1), #MDS (@Dr_AmerZeidan)
EBMT 2022
We recently interviewed @michaelwangmd of @MDAndersonNews to hear the results of the Phase I/II trial investigating sonrotoclax monotherapy in patients with R/R #MantleCellLymphoma who had previously been treated with a BTKi.
Click here to watch: 👉
Sonrotoclax monotherapy in R/R MCL previously treated with a BTKi: early Phase I/II results
Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents the early results of th...
ow.ly
We are thrilled to once again be the official media partner for the annual EBMT-EHA European CAR T-cell Meeting, which will take place in Palma de Mallorca, Spain, from 12–14 February! 🇪🇸
Want to join us there or attend virtually?
Register here:
👉 https://ow.ly/4WLv50XT1IT..
#ASH25 | @jenweiying of @MDAndersonNews shares results of the Phase II SAVE study evaluating the all-oral combination of revumenib, ASTX727, and venetoclax in newly diagnosed, unfit patients with NPM1-m or KMT2A-r AML.
Click here to watch:
🎥
#AMLsm
Phase II SAVE study of revumenib-based all-oral therapy in newly diagnosed AML
Wei-Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, The University of Texas MD Anderson Cancer Center, Houston, TX, ...
ow.ly
🎥 Karthik Ramasamy of @OUHospitals discusses the initial results from a cohort of the RADAR trial, which is evaluating the efficacy of Isa-VRDc induction and Isa-VRD consolidation in newly diagnosed transplant-eligible patients with double hit ultra-high risk #myeloma:
👉
The biggest #ASH25 takeaways, discussed by global experts 💡 🌍
Join our Post ASH 2025 Highlights webinar series 💻 🩸
🗓️ 22nd Jan - 11th Feb
Covering: #AML (@Daver_Leukemia) , Multiple #Myeloma, #CLL, #Lymphoma (@DrJasonWestin), #MPNs (@harrisoncn1), #MDS (@Dr_AmerZeidan)
